The partnership of Avipero and Fusion comes following new developments in Avipero's R&D and a record breaking year for Fusion Antibodies' Humanization service. "We are excited to be working with Avipero on their integrin antibodies and confident that Fusion Antibodies CDRx Humanization Platform will deliver high quality humanized antibodies that will accelerate the project into the clinic," says Dr
"This significant development will help strengthen the momentum of our development program and allow recent advances to progress seamlessly," says Dr.
The project is due to start in the next few weeks with early data expected over the summer.
About Fusion Antibodies
Fusion Antibodies; a
Fusion Antibodies has the knowledge and expertise to build and deliver a bespoke package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRx™ technology, they have modernized the traditional
Forward Looking Statements
Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO's dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.
Read the full story at http://www.prweb.com/releases/2014/05/prweb11864747.htm
Most Popular Stories
- Homeowners More Satisfied With Mortgage Servicers
- Discounts Help U.S. Auto Sales Sizzle in July
- Russia, Ukraine Now Face Off Over Football Clubs
- Colorado Issuing Immigrant Driver's Licenses
- Fiat Looks Abroad After Chrysler Merger Vote
- Chrysler U.S. Sales in July Hit 9-Year High
- MassMutual Teams Up With ALPFA
- Recruiting and Keeping the Perfect Employee
- Obama Vows to Veto House Immigration Bill
- Dow Wipes Out Gains for the Year: What Happens Now?